Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 3 Interventional Accepts healthy volunteers

Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease

ClinicalTrials.gov ID: NCT07839871

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07839871. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 3 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS VACCINE IN CHILDREN AT HIGH RISK OF RSV DISEASE

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of RSVpreF in children 5 to \<18 years of age at high risk for RSV disease, including those who are immunocompromised.

Study identification

NCT ID
NCT07839871
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
920 participants

Conditions and interventions

Interventions

Biological

Eligibility (public fields only)

Age range
5 Years to 17 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 22, 2026 (Actual)
Primary completion
Mar 30, 2031 (Estimated)
Completion
Mar 30, 2031 (Estimated)
Last update posted
Nov 6, 2026

2026 – 2031

United States locations

U.S. sites
5
U.S. states
3
U.S. cities
4
Facility City State ZIP Site status
Duke Vaccine and Trials Unit Durham North Carolina 27703 Recruiting
Cincinnati Children's Hospital Medical Center Vaccine Research Center Cincinnati Ohio 45206 Recruiting
Senders Pediatrics South Euclid Ohio 44121 Recruiting
Seattle Childrens Research Institute Seattle Washington 98101 Recruiting
Seattle Children's Hospital Seattle Washington 98105 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07839871, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 6, 2026 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.